Clinically, low MAO-B expression was associated with more aggressive tumor features and a poorer prognosis, while several MAO-B single-nucleotide polymorphisms were linked to greater prostate cancer metastasis capacity via decreased MAO-B enzymatic activity [63]. Here, MAOB is linked to neoplasm.